Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   283.69 (-1.13%)
AAPL   144.51 (-2.43%)
MSFT   242.18 (-2.15%)
META   109.35 (-1.85%)
GOOGL   96.19 (-1.30%)
AMZN   94.16 (+0.80%)
TSLA   184.54 (+0.92%)
NVDA   160.20 (-1.54%)
NIO   10.25 (+0.79%)
BABA   76.14 (+0.85%)
AMD   73.47 (-2.22%)
T   18.86 (-1.36%)
MU   56.22 (-3.75%)
CGC   3.41 (-6.83%)
F   13.72 (-2.56%)
GE   86.07 (-2.35%)
DIS   96.25 (-2.65%)
AMC   7.15 (-4.79%)
PYPL   80.70 (+0.77%)
PFE   49.40 (+0.39%)
NFLX   283.40 (-0.75%)
QQQ   283.69 (-1.13%)
AAPL   144.51 (-2.43%)
MSFT   242.18 (-2.15%)
META   109.35 (-1.85%)
GOOGL   96.19 (-1.30%)
AMZN   94.16 (+0.80%)
TSLA   184.54 (+0.92%)
NVDA   160.20 (-1.54%)
NIO   10.25 (+0.79%)
BABA   76.14 (+0.85%)
AMD   73.47 (-2.22%)
T   18.86 (-1.36%)
MU   56.22 (-3.75%)
CGC   3.41 (-6.83%)
F   13.72 (-2.56%)
GE   86.07 (-2.35%)
DIS   96.25 (-2.65%)
AMC   7.15 (-4.79%)
PYPL   80.70 (+0.77%)
PFE   49.40 (+0.39%)
NFLX   283.40 (-0.75%)
QQQ   283.69 (-1.13%)
AAPL   144.51 (-2.43%)
MSFT   242.18 (-2.15%)
META   109.35 (-1.85%)
GOOGL   96.19 (-1.30%)
AMZN   94.16 (+0.80%)
TSLA   184.54 (+0.92%)
NVDA   160.20 (-1.54%)
NIO   10.25 (+0.79%)
BABA   76.14 (+0.85%)
AMD   73.47 (-2.22%)
T   18.86 (-1.36%)
MU   56.22 (-3.75%)
CGC   3.41 (-6.83%)
F   13.72 (-2.56%)
GE   86.07 (-2.35%)
DIS   96.25 (-2.65%)
AMC   7.15 (-4.79%)
PYPL   80.70 (+0.77%)
PFE   49.40 (+0.39%)
NFLX   283.40 (-0.75%)
QQQ   283.69 (-1.13%)
AAPL   144.51 (-2.43%)
MSFT   242.18 (-2.15%)
META   109.35 (-1.85%)
GOOGL   96.19 (-1.30%)
AMZN   94.16 (+0.80%)
TSLA   184.54 (+0.92%)
NVDA   160.20 (-1.54%)
NIO   10.25 (+0.79%)
BABA   76.14 (+0.85%)
AMD   73.47 (-2.22%)
T   18.86 (-1.36%)
MU   56.22 (-3.75%)
CGC   3.41 (-6.83%)
F   13.72 (-2.56%)
GE   86.07 (-2.35%)
DIS   96.25 (-2.65%)
AMC   7.15 (-4.79%)
PYPL   80.70 (+0.77%)
PFE   49.40 (+0.39%)
NFLX   283.40 (-0.75%)
NASDAQ:ICPT

Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

$14.50
-0.27 (-1.83%)
(As of 11/28/2022 01:43 PM ET)
Add
Compare
Today's Range
$14.38
▼
$14.84
50-Day Range
$12.91
▼
$17.86
52-Week Range
$10.81
▼
$21.25
Volume
6,140 shs
Average Volume
914,582 shs
Market Capitalization
$600.55 million
P/E Ratio
2.53
Dividend Yield
N/A
Price Target
$25.80

Intercept Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
77.9% Upside
$25.80 Price Target
Short Interest
Bearish
10.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.13
Upright™ Environmental Score
News Sentiment
0.88mentions of Intercept Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.10) to ($2.45) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

189th out of 1,040 stocks

Pharmaceutical Preparations Industry

88th out of 509 stocks

See Top Rated MarketRank™ Stocks Here
ICPT stock logo

About Intercept Pharmaceuticals (NASDAQ:ICPT) Stock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Stock News Headlines

November 28, 2022 | americanbankingnews.com
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives $25.80 Average Price Target from Brokerages
November 22, 2022 | finance.yahoo.com
Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022
November 22, 2022 | americanbankingnews.com
Analysts Issue Forecasts for Intercept Pharmaceuticals, Inc.'s FY2022 Earnings (NASDAQ:ICPT)
November 8, 2022 | finance.yahoo.com
Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis
November 8, 2022 | finance.yahoo.com
Intercept Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
November 7, 2022 | seekingalpha.com
Intercept updates Phase 3 data for the NASH candidate
November 7, 2022 | finance.yahoo.com
Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022
November 6, 2022 | finance.yahoo.com
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022
November 4, 2022 | seekingalpha.com
Intercept Pharmaceuticals: Trying Times
November 2, 2022 | markets.businessinsider.com
Expert Ratings for Intercept Pharmaceuticals
November 2, 2022 | finance.yahoo.com
Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised
November 1, 2022 | finanznachrichten.de
Intercept Pharmaceuticals, Inc.: Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
October 30, 2022 | finance.yahoo.com
Shareholders in Intercept Pharmaceuticals (NASDAQ:ICPT) are in the red if they invested three years ago
October 25, 2022 | finance.yahoo.com
Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022
October 2, 2022 | finance.yahoo.com
Institutional owners may take dramatic actions as Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) recent 8.5% drop adds to one-year losses
September 30, 2022 | reuters.com
Intercept Pharma's liver disease drug fails late-stage trial
September 30, 2022 | seekingalpha.com
Intercept stock slumps 18% as liver disease drug fails phase 3 trial
September 30, 2022 | marketwatch.com
Intercept Pharmaceuticals Shares Slide After NASH Study Miss >ICPT
September 30, 2022 | finance.yahoo.com
Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients
September 30, 2022 | marketwatch.com
Intercept Phase 3 Compensated Cirrhosis NASH Study Misses Primary Endpoint >ICPT
September 30, 2022 | finance.yahoo.com
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
September 26, 2022 | finance.yahoo.com
Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
September 22, 2022 | markets.businessinsider.com
B.Riley Financial Reaffirms Their Buy Rating on Intercept Pharma (ICPT)
September 21, 2022 | finance.yahoo.com
Intercept Pharma Summarizes Key Actions in Strategic Financial Repositioning
September 21, 2022 | finance.yahoo.com
Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
See More Headlines
Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Company Calendar

Last Earnings
11/03/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/01/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ICPT
CUSIP
45845P10
CIK
1270073
Web
www.interceptpharma.com
Phone
(646) 747-1000
Fax
646-747-1001
Employees
437
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.80
High Stock Price Forecast
$49.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+77.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$5.74
Trailing P/E Ratio
2.53
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-91,430,000.00
Net Margins
62.47%
Pretax Margin
-45.54%
Return on Equity
N/A
Return on Assets
-34.09%

Debt

Debt-to-Equity Ratio
2.07
Current Ratio
2.46
Quick Ratio
2.46

Sales & Book Value

Annual Sales
$363.47 million
Price / Sales
1.65
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($6.23) per share
Price / Book
-2.33

Miscellaneous

Outstanding Shares
41,417,000
Free Float
32,719,000
Market Cap
$600.55 million
Optionable
Optionable
Beta
1.14

Key Executives

  • Mr. Jerome B. Durso (Age 54)
    Pres, CEO & Director
    Comp: $1.16M
  • Mr. Andrew Saik (Age 53)
    Chief Financial Officer
    Comp: $485.07k
  • Mr. Rocco Venezia (Age 46)
    Chief Accounting Officer & Treasurer
    Comp: $660.62k
  • Mr. Jared M. Freedberg J.D. (Age 54)
    Gen. Counsel
    Comp: $691.46k
  • Dr. M. Michelle Berrey M.D. (Age 55)
    M.P.H., MPH., Pres of R&D and Chief Medical Officer
    Comp: $732.13k
  • Mr. Nareg Sagherian
    Exec. Director of Global Investor Relations
  • Mr. David Ford (Age 52)
    Chief HR Officer
  • Dr. Mark Pruzanski M.D. (Age 54)
    Founder, Advisor & Director
  • Ms. Linda M. Richardson (Age 58)
    Exec. VP & Chief Commercial Officer
  • Paul Nitschmann
    Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ICPT Stock - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ICPT shares.
View ICPT analyst ratings or view top-rated stocks.

What is Intercept Pharmaceuticals' stock price forecast for 2023?

8 Wall Street research analysts have issued twelve-month price objectives for Intercept Pharmaceuticals' stock. Their ICPT share price forecasts range from $14.00 to $49.00. On average, they anticipate the company's share price to reach $25.80 in the next twelve months. This suggests a possible upside of 74.7% from the stock's current price.
View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts.

How have ICPT shares performed in 2022?

Intercept Pharmaceuticals' stock was trading at $16.29 at the beginning of 2022. Since then, ICPT shares have decreased by 9.3% and is now trading at $14.77.
View the best growth stocks for 2022 here.

When is Intercept Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our ICPT earnings forecast.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.00) by $0.89. The biopharmaceutical company had revenue of $92.80 million for the quarter, compared to analysts' expectations of $83.04 million. The firm's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.01) earnings per share.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $340.00 million-$350.00 million, compared to the consensus revenue estimate of $312.94 million.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.09%), Vanguard Group Inc. (6.53%), Point72 Asset Management L.P. (3.76%), Jacobs Levy Equity Management Inc. (1.89%), Renaissance Technologies LLC (1.78%) and Macquarie Group Ltd. (1.58%). Insiders that own company stock include Christian Weyer, David A Ford, Gail Cawkwell, Jason Campagna, Mark Pruzanski, Paolo Fundaro, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $14.77.

How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $611.73 million and generates $363.47 million in revenue each year. The biopharmaceutical company earns $-91,430,000.00 in net income (profit) each year or $5.74 on an earnings per share basis.

How many employees does Intercept Pharmaceuticals have?

The company employs 437 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001.

This page (NASDAQ:ICPT) was last updated on 11/28/2022 by MarketBeat.com Staff